These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30976971)

  • 1. A predictive formula for selecting individual FSH starting dose based on ovarian reserve markers in IVF/ICSI cycles.
    Zhu M; Wang S; Yi S; Huang X; Meng J; Chen L; Sun H; Zhou J
    Arch Gynecol Obstet; 2019 Aug; 300(2):441-446. PubMed ID: 30976971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study.
    Si M; Qi X; Zhen X; Yang C; Tian T; Long X; Qiao J
    Adv Ther; 2023 Sep; 40(9):3971-3985. PubMed ID: 37395872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol.
    Wu S; Li Y; Wu G; Wu H
    BMC Womens Health; 2023 Apr; 23(1):202. PubMed ID: 37118751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the anti-Müllerian hormone truly reflect ovarian response in women with endometrioma?
    Inal ZO; Engin Ustun Y; Yilmaz N; Aktulay A; Bardakci Y; Gulerman C
    J Obstet Gynaecol; 2019 May; 39(4):516-521. PubMed ID: 30744464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles.
    La Marca A; Papaleo E; Grisendi V; Argento C; Giulini S; Volpe A
    BJOG; 2012 Sep; 119(10):1171-9. PubMed ID: 22805536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of different starting doses of FSH on laboratory and clinical outcomes in patients with moderate AMH level.
    Liu M; Wang C; He L; Pan X; Wu C; Pu X; Pan X
    Hormones (Athens); 2024 Jun; 23(2):331-338. PubMed ID: 38342850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count.
    La Marca A; Grisendi V; Giulini S; Argento C; Tirelli A; Dondi G; Papaleo E; Volpe A
    J Ovarian Res; 2013 Feb; 6(1):11. PubMed ID: 23388048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study.
    Papaleo E; Zaffagnini S; Munaretto M; Vanni VS; Rebonato G; Grisendi V; Di Paola R; La Marca A
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():94-99. PubMed ID: 27835829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the likely IVF/ICSI outcomes if there is a discrepancy between serum AMH and FSH levels? A multicenter retrospective study.
    Daney de Marcillac F; Pinton A; Guillaume A; Sagot P; Pirrello O; Rongieres C
    J Gynecol Obstet Hum Reprod; 2017 Oct; 46(8):629-635. PubMed ID: 28843783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of cystectomy for ovary benign cyst on ovarian reserve and pregnancy outcome of in vitro fertilization-embryo transfer cycle].
    Zhang XR; Ding LL; Tang R; Sheng Y; Qin YY; Chen ZJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 Mar; 51(3):180-5. PubMed ID: 27030496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
    Andersen AN; Witjes H; Gordon K; Mannaerts B;
    Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization.
    Lukaszuk K; Kunicki M; Liss J; Lukaszuk M; Jakiel G
    Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):173-7. PubMed ID: 23485092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ala307Thr polymorphism of the follicle-stimulating hormone receptor (FSHR) gene is associated with the dose of recombinant FSH received during IVF/ICSI treatment.
    Dieamant F; Petersen CG; Vagnini LD; Petersen B; Ricci J; Nicoletti A; Zamara C; Oliani AH; Oliveira JBA; Franco JG
    JBRA Assist Reprod; 2023 Mar; 27(1):78-84. PubMed ID: 36995260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.
    Oehninger S; Nelson SM; Verweij P; Stegmann BJ
    Reprod Biol Endocrinol; 2015 Oct; 13():117. PubMed ID: 26520396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do ovarian endometriomas affect ovarian response to ovarian stimulation for IVF/ICSI?
    González-Foruria I; Soldevila PB; Rodríguez I; Rodríguez-Purata J; Pardos C; García S; Pascual MÁ; Barri PN; Polyzos NP
    Reprod Biomed Online; 2020 Jul; 41(1):37-43. PubMed ID: 32456967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.